Browse HSD17B12

Summary
SymbolHSD17B12
Namehydroxysteroid (17-beta) dehydrogenase 12
Aliases KAR; SDR12C1; 3-ketoacyl-CoA reductase; short chain dehydrogenase/reductase family 12C, member 1; 17-beta-HS ......
Chromosomal Location11q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endoplasmic reticulum membrane Multi-pass membrane protein
Domain PF00106 short chain dehydrogenase
Function

Catalyzes the second of the four reactions of the long-chain fatty acids elongation cycle. This endoplasmic reticulum-bound enzymatic process, allows the addition of two carbons to the chain of long- and very long-chain fatty acids/VLCFAs per cycle. This enzyme has a 3-ketoacyl-CoA reductase activity, reducing 3-ketoacyl-CoA to 3-hydroxyacyl-CoA, within each cycle of fatty acid elongation. Thereby, it may participate in the production of VLCFAs of different chain lengths that are involved in multiple biological processes as precursors of membrane lipids and lipid mediators. May also catalyze the transformation of estrone (E1) into estradiol (E2) and play a role in estrogen formation.

> Gene Ontology
 
Biological Process GO:0006631 fatty acid metabolic process
GO:0006633 fatty acid biosynthetic process
GO:0006637 acyl-CoA metabolic process
GO:0006694 steroid biosynthetic process
GO:0006703 estrogen biosynthetic process
GO:0006732 coenzyme metabolic process
GO:0006790 sulfur compound metabolic process
GO:0008202 steroid metabolic process
GO:0008210 estrogen metabolic process
GO:0009108 coenzyme biosynthetic process
GO:0010810 regulation of cell-substrate adhesion
GO:0010811 positive regulation of cell-substrate adhesion
GO:0010817 regulation of hormone levels
GO:0016053 organic acid biosynthetic process
GO:0030198 extracellular matrix organization
GO:0031589 cell-substrate adhesion
GO:0034754 cellular hormone metabolic process
GO:0035336 long-chain fatty-acyl-CoA metabolic process
GO:0035337 fatty-acyl-CoA metabolic process
GO:0035338 long-chain fatty-acyl-CoA biosynthetic process
GO:0035383 thioester metabolic process
GO:0035384 thioester biosynthetic process
GO:0042445 hormone metabolic process
GO:0042446 hormone biosynthetic process
GO:0043062 extracellular structure organization
GO:0044272 sulfur compound biosynthetic process
GO:0044283 small molecule biosynthetic process
GO:0045785 positive regulation of cell adhesion
GO:0046394 carboxylic acid biosynthetic process
GO:0046949 fatty-acyl-CoA biosynthetic process
GO:0051186 cofactor metabolic process
GO:0051188 cofactor biosynthetic process
GO:0071616 acyl-CoA biosynthetic process
GO:0072330 monocarboxylic acid biosynthetic process
Molecular Function GO:0001968 fibronectin binding
GO:0003857 3-hydroxyacyl-CoA dehydrogenase activity
GO:0004303 estradiol 17-beta-dehydrogenase activity
GO:0005518 collagen binding
GO:0005539 glycosaminoglycan binding
GO:0008201 heparin binding
GO:0016229 steroid dehydrogenase activity
GO:0016509 long-chain-3-hydroxyacyl-CoA dehydrogenase activity
GO:0016614 oxidoreductase activity, acting on CH-OH group of donors
GO:0016616 oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor
GO:0033764 steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor
GO:0102339 3-oxo-arachidoyl-CoA reductase activity
GO:0102340 3-oxo-behenoyl-CoA reductase activity
GO:0102341 3-oxo-lignoceroyl-CoA reductase activity
GO:1901681 sulfur compound binding
Cellular Component GO:0005578 proteinaceous extracellular matrix
> KEGG and Reactome Pathway
 
KEGG hsa00062 Fatty acid elongation
hsa00140 Steroid hormone biosynthesis
hsa01040 Biosynthesis of unsaturated fatty acids
hsa01100 Metabolic pathways
hsa01212 Fatty acid metabolism
Reactome R-HSA-193048: Androgen biosynthesis
R-HSA-75105: Fatty Acyl-CoA Biosynthesis
R-HSA-535734: Fatty acid, triacylglycerol, and ketone body metabolism
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-196071: Metabolism of steroid hormones
R-HSA-209943: Steroid hormones
R-HSA-75876: Synthesis of very long-chain fatty acyl-CoAs
R-HSA-75109: Triglyceride Biosynthesis
Summary
SymbolHSD17B12
Namehydroxysteroid (17-beta) dehydrogenase 12
Aliases KAR; SDR12C1; 3-ketoacyl-CoA reductase; short chain dehydrogenase/reductase family 12C, member 1; 17-beta-HS ......
Chromosomal Location11q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between HSD17B12 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolHSD17B12
Namehydroxysteroid (17-beta) dehydrogenase 12
Aliases KAR; SDR12C1; 3-ketoacyl-CoA reductase; short chain dehydrogenase/reductase family 12C, member 1; 17-beta-HS ......
Chromosomal Location11q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of HSD17B12 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell logFC: -2.00; FDR: 0.04220 Resistant to T cell-mediated killing
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolHSD17B12
Namehydroxysteroid (17-beta) dehydrogenase 12
Aliases KAR; SDR12C1; 3-ketoacyl-CoA reductase; short chain dehydrogenase/reductase family 12C, member 1; 17-beta-HS ......
Chromosomal Location11q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of HSD17B12 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3820.208
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.4750.846
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3190.852
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0210.942
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3430.81
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3820.826
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0270.952
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0040.998
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0790.97
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1170.939
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.1540.947
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0350.653
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of HSD17B12 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolHSD17B12
Namehydroxysteroid (17-beta) dehydrogenase 12
Aliases KAR; SDR12C1; 3-ketoacyl-CoA reductase; short chain dehydrogenase/reductase family 12C, member 1; 17-beta-HS ......
Chromosomal Location11q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HSD17B12. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolHSD17B12
Namehydroxysteroid (17-beta) dehydrogenase 12
Aliases KAR; SDR12C1; 3-ketoacyl-CoA reductase; short chain dehydrogenase/reductase family 12C, member 1; 17-beta-HS ......
Chromosomal Location11q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HSD17B12. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HSD17B12.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolHSD17B12
Namehydroxysteroid (17-beta) dehydrogenase 12
Aliases KAR; SDR12C1; 3-ketoacyl-CoA reductase; short chain dehydrogenase/reductase family 12C, member 1; 17-beta-HS ......
Chromosomal Location11q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HSD17B12. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolHSD17B12
Namehydroxysteroid (17-beta) dehydrogenase 12
Aliases KAR; SDR12C1; 3-ketoacyl-CoA reductase; short chain dehydrogenase/reductase family 12C, member 1; 17-beta-HS ......
Chromosomal Location11q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of HSD17B12 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolHSD17B12
Namehydroxysteroid (17-beta) dehydrogenase 12
Aliases KAR; SDR12C1; 3-ketoacyl-CoA reductase; short chain dehydrogenase/reductase family 12C, member 1; 17-beta-HS ......
Chromosomal Location11q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between HSD17B12 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolHSD17B12
Namehydroxysteroid (17-beta) dehydrogenase 12
Aliases KAR; SDR12C1; 3-ketoacyl-CoA reductase; short chain dehydrogenase/reductase family 12C, member 1; 17-beta-HS ......
Chromosomal Location11q11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting HSD17B12 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.